FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
15 | Clinico-pathological features of superficial angiosarcomas: a retrospective study Lorenzo Bellando1, Chiara Anselmo2, Giulia Orlando3, Leonardo Panarelli2, Pietro Cosentino2, Pietro Quaglino4, Franco Picciotto5, Simone Ribero4, Rebecca Senetta3 | 1Pathology Unit, Città Della Salute e Della Scienza of Turin, University of Turin; 2Department of Medical Sciences, Pathology Unit, University of Turin; 3Department of Oncology, Pathology Unit, University of Turin; 4Department of Medical Sciences, Section of Dermatology, University of Turin; 5Department of Surgery, Dermatologic Surgery Section, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin, Italy.
332 -
30 | Sonidegib for nevoid basal cell carcinoma (Gorlin) syndrome and EADO stage IIb sporadic basal cell carcinomas: a phase II study (SIBLINGS trial) Sara Farinatti1|2, Giuseppe Agenziano3, Emi Dika4|5, Emanuela Passoni6, Ketty Peris7, Pietro Quaglino8, Paola Queirolo9, Massimiliano Scalvenzi10, Iris Zalaudek11, Luigi Lorini11, Cristina Gurizzan1, Monica Variolo1|2, Paolo Bossi*1|2, Carlo Resteghini*1|2 | 1Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milano; 2Department of Biomedical Sciences, Humanitas University, Rozzano MI; 3Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; 4Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna; 5Department of Medical and Surgical Sciences, DIMEC, University of Bologna, Bologna; 6Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; 7Institute of Dermatology, Catholic University of the Sacred Heart, Rome; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; 8Dermatologic Clinic, University of Turin Medical School, Turin; 9Medical Oncology Unit; 10Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples; 11Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste, Italy. *Contributed equally.
336 -
23 | Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: an international retrospective study Maria Chiara Sergi*1, Teresa Amaral*2, Piotr Rutkowski*3, Marie-Lena Rasch2, Naima Benannoune4, Patricio Serra5, Maria Grazia Vitale6, Diana Giannarelli7, Ana Maria Arance8, Eva Munoz Couselo9, Bart Neyns10, Iris Dirven11, Marco Tucci12, Michele Guida13, Francesco Spagnolo14, Ernesto Rossi15, Paola Queirolo16, Pietro Quaglino17, Roberta Depenni18, Joanna Placzke3, Anna Maria Di Giacomo19, Michele Del Vecchio20, Alice Indini20, Ines Pires da Silva21, Alexander M. Menzies22, Angela Hong23, Paul Lorigan5, Caroline Robert24, Georgina V. Long22, Paolo A. Ascierto6, Mario Mandalà25 | 1Unit of Medical Oncology, "Mons. A.R. Dimiccoli" Hospital, Asl BT, Barletta, Italy; 2Skin Cancer Clinical Trials Center, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. 3Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 4Gustave Roussy Cancer Campus, Villejuif, France. 5The University of Manchester, Manchester, UK. 6Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, I.N.T. IRCCS Fondazione "G. Pascale" Napoli, Naples, Italy; 7Epidemiology and Biostatistics, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; 8Hospital Clínic Barcelona and IDIBAPS, Barcelona, Spain; 9Department of medical oncology. Vall d"Hebron Hospital, Barcelona, Spain & Vall d’Hebron Institute of oncology, VHIO. Barcelona, Spain; 10Department of Medical Oncology, UZ Brussel, Brussels, Belgium. 11Department of medical oncology, Vrije Universiteit Brussel, VUB, Universitair Ziekenhuis Brussel, Brussels, Belgium; 12Medical Oncology Unit, University of Bari Aldo Moro, Policlinico Hospital of Bari, 70124 Bari, Italy. 13Rare Tumors and Melanoma Unit, IRCCS Istituto dei Tumori "Giovanni Paolo II," Bari, Italy. 14IRCCS Ospedale Policlinico San Martino, Skin Cancer Unit, Genova, Italy; 15Medical Oncology, Fondazione Policlinico Universitario, A. Gemelli IRCCS, Rome, Italy; 16IEO European Institute of Oncology, IRCCS, Milan, Italy. 17Department of Dermatology, University of Turin, Turin, Italy. 18University of Modena and Reggio Emilia, Department of Oncology, Hematology, Modena, Emilia-Romagna, Italy; 19Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy. 20Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 21Melanoma Institute Australia, University of Sydney, and Blacktown Hospital, Sydney, New South Wales, Australia; 22Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; 23Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Australia; Department of Radiation Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia; 24Gustave Roussy and Paris-Saclay University, Villejuif, France; 25Unit of Medical Oncology, University of Perugia, Perugia, Italy. § on behalf of the Italian Melanoma Intergroup - IMI.
292 -
17 | The role of sentinel lymph node biopsy in pt1a, pt1b and pt2a melanomas: a 10-year experience through 2025 Gabriele Roccuzzo1, Nicolas Destefanis2, Giulia Orlando3, Eleonora Bergamo1, Virginia Caliendo4, Adriana Lesca5, Daniela Zugna2, Franco Picciotto4, Rebecca Senetta3, Simone Ribero1, Pietro Quaglino1 | 1Department of Medical Sciences, Section of Dermatology, University of Turin; 2Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin; 3Department of Oncology, Section of Surgical Pathology, University of Turin; 4Dermatologic Surgery Section, Department of Surgery, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin; 5Division of Nuclear Medicine, Department of Medical Science, University of Turin, Italy.
304 -
02 | Melanoma training in primary care: comparing traditional teaching with telemedicine-enhanced education. A review Giorgia Ravaglia1, Edoardo Mora2, Debora Cantagalli3, Serena Magi4, Laura Mazzoni4, Matelda Medri4, Cesare Massone5, Davide Melandri6, Federica Zamagni7, Ines Zanna8, Gianluca Pistore9, Saverio Caini8, Salvatore Amato10, Vincenzo De Giorgi11, Pietro Quaglino12, Maria Antonietta Pizzichetta13|14, Giovanni Luigi Tripepi15, Sofia Spagnolini1, Ignazio Stanganelli1|4 | 1Dermatology Resident Training Program, Department of Medicine and Surgery, University of Parma, Parma; 2Dermatology Unit, Ospedale S. Anna, Como; 3Primary Care Resident Training program, Ausl Bologna, Bologna; 4Skin Cancer Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" – IRST Meldola, Forlì-Cesena; 5Dermatology Unit, Ospedali Galliera, Genova; 6Dermatology Unit, AUSL Romagna and University of Bologna, Cesena. 7Registro Tumori della Regione Emilia Romagna, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST Meldola, Forlì-Cesena; 8Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network, ISPRO, Florence; 9Clinical Epidemiology Unit, Istituto Dermopatico dell’Immacolata - IRCCS, Rome; 10Associazione Dermatologi Ospedalieri Italiani, ADOI, Sicilia and Teledermatology working group, Palermo; 11Dermatology, Department of Health Sciences, University of Florence, Florence; 12Dermatologic Clinic, Department of Medical Sciences, University of Turin, Torino; 13Department of Dermatology, University of Trieste, Trieste; 14Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano, CRO, IRCCS, Aviano; 15CNR-IFC, Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension, Reggio Calabria, Italy.
376 -
34 | Dissecting the spectrum of rare BRAF mutations in melanoma: a nation-wide study by the Italian Melanoma Intergroup Francesco Spagnolo1|2, Bruna Dalmasso3, Maria Chiara Scaini4, Laura Cendron5, Monica Rodolfo6, Ilaria Mattavelli7, Elena Tamborini8, Francesca Collina9, Gerardo Ferrara, Gabriele Madonna10, Carlo Cota11, Elisa Melucci12, Stefania Tommasi13, Martina Ubaldi14, Roberta Depenni15, Andrea Carugno16, Riccardo Marconcini17, Laura Orgiano18, Maurizio Lombardo19, Simona Sola20, Cristina Pellegrini21, Francesca Castiglione22, Matteo Gasparotto5|23, Alireza Jorkesh5, Stefania Pellegrini4, Edoardo Raposio1, Andrea Boutros2, Enrica Teresa Tanda2, Michele Guida25, Pietro Quaglino26, Giuseppe Palmieri27, Daniela Massi22, Paolo Antonio Ascierto10, Mario Mandalà*28, Chiara Menin*4, Paola Ghiorzo*24, Lorenza Pastorino*24, for the Italian Melanoma Intergroup29 | 1Department of Surgical Sciences and Integrated Diagnostics, DISC, Plastic Surgery Division, University of Genoa; 2IRCCS Ospedale Policlinico San Martino, Genova; 3IRCCS Ospedale Policlinico San Martino, Cancer Genetics, Genoa; 4Immunology and Molecular Oncology Unit, Veneto Institute of Oncology - IOV IRCCS, Padua; 5Department of Biology, University of Padua, Padua; 6Unit of Translational Immunology, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 7Melanoma Surgical Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 8Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 9Pathology Unit, Istituto Nazionale Tumori, IRCCS - Fondazione G. Pascale, Napoli; 10Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli; 11Dermatopathology Unit, San Gallicano Dermatological Institute IRCCS, Rome; 12Pathology Unit, IRCCS Regina Elena, National Cancer Institute, Rome; 13Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari; 14Unit of Medical Oncology, University of Perugia; 15Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena; 16Department of Medicine and Surgery, University of Insubria, Varese; 17Medical Oncology Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa; 18Department of Medical Oncology, University of Cagliari, Cagliari; 19Division of Dermatology, Department of Medicine and Surgery, Ospedale di Circolo e Fondazione Macchi, ASST dei Sette Laghi, Varese; 20Surgical Pathology, Galliera Hospital, Genoa; 21Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila; 22Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy and Section of Pathology, Department of Health Sciences, University of Florence, Italy; 23Department of Translational Brain Research, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 24Department of Internal Medicine and Medical Specialties, University of Genoa; 25Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari; 26Dermatology Clinic, Department of Medical Sciences, University of Turin; 27Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari - Unit of Cancer Genetics, IRGB-CNR, Sassari; 28University of Perugia, Medical Oncology Unit, Santa Maria Misericordia Hospital, Perugia; 29Italian Melanoma Intergroup, IMI, Italy. *These authors equally contributed to this work.
320 -
14 | Unraveling the transcriptomic landscape of poorly differentiated cutaneous squamous cell carcinoma: toward prognostic biomarkers Lorenzo Bellando1, Chiara Anselmo2, Giulia Orlando3, Leonardo Panarelli2, Ilaria Palma2, Virginia Caliendo3, Franco Picciotto4, Gabriele Roccuzzo5, Pietro Quaglino5, Simone Ribero5, Rebecca Senetta3 | 1Pathology Unit, Città Della Salute e Della Scienza University of Turin; 2Department of Medical Sciences, Pathology Unit, University of Turin; 3Department of Oncology, Pathology Unit, University of Turin; 4Department of Surgery, Dermatologic Surgery Section, Azienda Ospedaliera Universitaria Città della Salute e della Scienza of Turin; 5Department of Medical Sciences, Section of Dermatology, University of Turin, Italy.
328
1 - 7 of 7 items
